Exciting news for Belgian biotech! 🚀 Belgian astronaut Raphaël Liégeois will head to the International Space Station (ISS) in Fall 2026. BELSPO, supported by the European Space Agency - ESA, has launched a call for Belgian research proposals to utilize the ISS for groundbreaking research. 🔬 Key details: - Call deadline: 13 September 2024 - Notification: End of Q4 2024 - Kick-off: Early 2025 - Launch: Fall 2026 Focus areas include advanced biological research, improved drug development, enhanced tissue engineering, and optimized food production. Belgian industry partner Space Applications Services NV/SA can support with their ICE Cubes capabilities. Seize this unique chance to advance your research in microgravity! 🛰️ Find out more via: bit.ly/3y54nUC Photo: © ESA, Columbus module on ISS
flanders.bio
Biotechnology Research
Ghent, Flemish Region 12,525 followers
the cluster organisation empowering a life sciences driven network economy.
About us
flanders.bio is the cluster organisation empowering a life sciences driven network economy. We help our members to create value by organising networking and training activities, supporting internationalisation, providing services and building expertise.
- Website
-
https://www.flanders.bio
External link for flanders.bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Ghent, Flemish Region
- Type
- Nonprofit
- Founded
- 2004
- Specialties
- Biotechnology, life sciences, Sector organisation, MedTech, Agrotechnology, biotech, healthcare, Cluster, and agtech
Locations
-
Primary
Technologiepark-Zwijnaarde 122
AA Tower
Ghent, Flemish Region 9052, BE
Employees at flanders.bio
-
Wouter Piepers
Connecting dots in Biotech and Life Sciences | Ecosystem Builder | CEO of flanders.bio | Seasoned International Investor Relations & Communications…
-
Stefan Thys
Program Manager at argenx
-
Tom Aelbrecht
Head of Sustainable Business Strategy and Reporting (J&J Belgium)
-
Toon Musschoot
Head Investor Relations and Communications at Biotalys NV | Member of the Senior Leadership Team | Board Member at flanders.bio
Updates
-
ONTOFORCE, the provider of DISQOVER, a leading knowledge discovery platform for the life sciences industry, is pleased to announce that it has achieved the ISO 27001:2022 certification. This prestigious certification underscores the company’s dedication to maintaining the highest standards of information security, ensuring that their customers can trust ONTOFORCE and its knowledge discovery platform DISQOVER with their most sensitive data.
-
etherna last week announced the appointment of Antonin (Tony) de Fougerolles as Chair. Tony has served as an Independent Board Member since January 2023. Outgoing Chair, Marijn Dekkers will remain on the Board. In addition to his role as Chair, Tony will also take an active consultancy role for the Company. Tony de Fougerolles has foundational experience in both #mRNA therapeutics and #LNPs specifically through his roles at Moderna and Alnylam. He has nearly 25 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities to the market (mRNA, RNAi, single domain antibodies) and in helping build several multi-billion-dollar companies from startup stage.
Antonin (Tony) de Fougerolles appointed as new Chair of etherna
flanders.bio
-
How can we accelerate the delivery of innovative #health techniques and products to patients who need it? By working together to make cell, gene and tissue related therapies available to all European citizens! 💡 That’s why eight European organisations - including flanders.bio - joined forces in the European Hub for Advanced Development in Regenerative Medicine and Biomaterials (EHAB). By building a European interconnected value chain, the #EHAB will identify regional strengths, weaknesses, gaps and needs. 🇪🇺 Stay updated on our progress in strengthening the European landscape in Advanced Therapies and Biomaterials (AT&B) by following the EHAB page! ☝🏼 🫱🏽🫲🏾 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 BOM (Brabantse Ontwikkelings Maatschappij) (🇳🇱) - Brightlands Maastricht Health Campus (🇳🇱) - BioRegio STERN Management GmbH (🇩🇪) - A4TEC Association (🇵🇹) - Biocat, BioRegion of Catalonia (🇪🇸) - RISE Research Institutes of Sweden (🇸🇪) - MedSilesia Cluster - Silesian Medical Devices Network (🇵🇱) - flanders.bio (🇧🇪) 🙌🏽 𝗘𝗻𝗱𝗼𝗿𝘀𝗲𝗿𝘀 Provincie Noord-Brabant - Provincie Limburg - RegMed XB - Departement Economie, Wetenschap en Innovatie (EWI) - Vanguard Initiative - Generalitat de Catalunya - Leitat Technological Center - AseBio - Asociación Española de Bioempresas - Vall d'Hebron Institute of Oncology (VHIO) - Fraunhofer IPA. Funded by the European Union.
-
-
Trince, an innovative spin-off from Universiteit Gent, wins the global Spinoff Prize from the scientific journal Nature, beating two American and one British opponent. With the award, the world-renowned journal aims to highlight spin-offs that translate original and excellent research in the life sciences or physical sciences into practical applications with added value for society.
Ghent University spin-off Trince wins Nature Spinoff Prize
flanders.bio
-
Agomab announced that Pierre Kemula will join the company as Chief Financial Officer, bringing more than 15 years of experience in global biotech financial leadership.
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
flanders.bio
-
Agomab announced that it has appointed David Epstein as non-executive board member and Chairman of its Board of Directors. Epstein is an industry veteran and most recently served as Seagen’s Chief Executive Officer and as a member of its Board of Directors. Prior to Seagen, he served as Novartis Pharmaceuticals’ Chief Executive Officer. Epstein has more than 30 years of drug development, deal-making, commercialization and leadership experience on a global scale. Over the course of his career, he has led the development and commercialization of over 30 new molecular entities.
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
flanders.bio
-
Welcome to our new member Muna Therapeutics! Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s and Parkinson’s. The company focuses its groundbreaking science on identifying new medicines to preserve cognition and other brain functions, enhance resilience to disease pathology, and slow or stop the progression of neurodegenerative diseases.
Muna Therapeutics
flanders.bio
-
mdxhealth, a commercial-stage precision diagnostics company, today announced the appointment of Dr. Sanford Siegel, M.D. to its Board of Directors. Dr. Siegel has more than 45 years of experience as a practicing urologist and over 35 years of executive leadership experience.
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors
flanders.bio
-
NEWS ALERT: Patrik De Haes is the new CEO of our organisation ! Patrik: "I look forward to working with the team, our members, and the Board of Directors. Together, we will continue to strengthen Flanders' position as a #lifesciences industry leader." We wish Patrik much success in his new role and are confident he will do fantastic work. He succeeds Wouter Piepers, who has led flanders.bio since May 2022. We are also saying goodbye to Willem Dhooge, our COO, who will soon embark on a new adventure. We want to thank both Wouter and Willem for their hard work and dedication in the past years. They will continue to support our organisation with advice in the coming months. You can read the full press release on our website: https://lnkd.in/eDPx6fpr
flanders.bio is gearing up for the future, under the leadership of new CEO, Patrik De Haes
flanders.bio